Welcome to our dedicated page for Six Circles Multi-Strategy news (Ticker: CALTX), a resource for investors and traders seeking the latest updates and insights on Six Circles Multi-Strategy stock.
Six Circles Multi-Strategy (CALTX) is a biopharmaceutical innovator developing targeted therapies for rare kidney diseases and oncology. This page aggregates official press releases and verified news about clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find updates on the company’s IgA nephropathy (IgAN) program—including its FDA-recognized orphan drug candidate—and oncology developments featuring novel NOX inhibitors. Content spans trial results, intellectual property updates, and partnership announcements across global markets.
All materials are curated to meet investor needs for decision-critical information while maintaining compliance with financial disclosure standards. Key focus areas include treatment efficacy data, regulatory submissions, and market expansion strategies in Asia and Europe.
Bookmark this page for structured access to Six Circles Multi-Strategy’s latest developments. Check regularly for updates on clinical progress and therapeutic innovations in specialty medicine.
On April 26, 2023, Calliditas Therapeutics announced the availability of its 2022 Annual Report on the company's website. The report provides insights into the company's performance, including developments in their lead product, Nefecon, which received FDA accelerated approval as TARPEYO® and conditional marketing authorization in the EU as Kinpeygo®. Additionally, Calliditas is advancing clinical trials for its NOX inhibitor product candidate, setanaxib, targeting primary biliary cholangitis and head & neck cancer. Contact for investor relations is Åsa Hillsten, available via phone or email. The company cautioned that the report contains forward-looking statements that are subject to risks and uncertainties regarding future performance.
Calliditas Therapeutics (NASDAQ: CALT, CALTX) announced its participation in two upcoming investor conferences. The first is the Guggenheim Genomic Medicines and Rare Disease Days Conference on April 3, 2023, in New York, featuring a fireside chat with CEO Renee Aguiar-Lucander and a KOL panel on IgA nephropathy treatment. The second event is the Kempen Life Sciences Conference in Amsterdam on April 25-26, 2023. Both conferences will include one-on-one meetings with investors, emphasizing Calliditas' commitment to developing innovative therapies for renal and hepatic diseases.
Everest Medicines announced that its partner Calliditas Therapeutics reported positive topline results from the Phase 3 clinical trial NefIgArd, evaluating Nefecon in patients with primary IgA nephropathy (IgAN). The trial met its primary endpoint, showing a statistically significant improvement in estimated glomerular filtration rate (eGFR) with Nefecon compared to placebo (p < 0.0001). Results indicated an average eGFR increase of 5.05 mL/min/1.73 m2 with Nefecon. The treatment appears well-tolerated, supporting its efficacy as a disease-modifying therapy. Calliditas plans to seek full FDA approval and additional regulatory submissions in 2023.
